Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: Recommendations of HDL Forum

被引：22

作者：

Ascaso J.F. ^{[1
]}

Fernández-Cruz A. ^{[2
]}

González Santos P. ^{[3
]}

Hernández Mijares A. ^{[4
]}

Mangas Rojas A. ^{[5
]}

Millán J. ^{[6
]}

Pallardo L.F. ^{[7
]}

Pedro-Botet J. ^{[8
]}

Pérez-Jiménez F. ^{[9
]}

Pía G. ^{[10
]}

Pintó X. ^{[11
]}

Plaza I. ^{[12
]}

Rubiés-Prat J. ^{[13
]}

机构：

[1] Endocrinology Service, Clinic University Hospital, University of Valencia, Valencia

[2] Cardiovascular Institute, Hospital Clinico San Carlos, Complutense University of Madrid, Madrid

[3] Department of Internal Medicine, Univ. Hospital Virgen de la Victoria, Málaga

[4] Endocrinology Service, Peset University Hospital, University of Valencia, Valencia

[5] Internal Medicine Service, Puerta del Mar University Hospital, Cádiz

[6] Internal Medicine Service, Gen. Univ. Hospital Gregorio Maranon, E-28007 Madrid

[7] Endocrinology and Nutrition Service, La Paz University Hospital, Madrid

[8] Department of Internal Medicine, Hospital del Mar, Universidad Autonoma de Barcelona, Barcelona

[9] Lipid and Atherosclerosis Unit, Internal Medicine Service, Reina Sofia University Hospital, Cordoba

[10] Internal Medicine Service, Hosp. Arq. Marcide-Prof. N. Santos, Ferrol

[11] Lipid and Atherosclerosis Unit, Internal Medicine Service, Bellvitge University Hospital, Barcelona

[12] Cardiology Service, La Paz University Hospital, Madrid

[13] Department of Medicine, Universidad Autonoma de Barcelona, Barcelona

来源：

American Journal of Cardiovascular Drugs | 2004年 / 4卷 / 5期

关键词：

Fenofibrate; Gemfibrozil; Fibric Acid Derivative; Cardiovasc Drug; Ischemic Heart Disease Risk;

D O I：

10.2165/00129784-200404050-00003

中图分类号：

学科分类号：

摘要：

In the approach to lipid-related risk factors for cardiovascular diseases, serum high density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the 'low HDL syndrome' with the metabolic syndrome. These factors force us to consider serum HDL-C level as a therapeutic target by itself, or even in association with low density lipoprotein-cholesterol (LDL-C) levels when the latter are increased. This review stresses the aspects connecting serum HDL-C levels and cardiovascular risk, and looks at the populations that should be considered amenable to therapeutic management because of low serum HDL-C levels. We review therapeutic strategies, both pharmacological and nonpharmacological. The aim of this review is to present therapeutic management recommendations for correcting the proportion of cardiovascular risk that is attributable to changes in HDL-C. Serum HDL-C levels of >40 mg/dL must be a therapeutic target in primary and secondary prevention. This goal is particularly important in patients with low serum HDL-C levels and ischemic heart disease (IHD) or its equivalents, even if the therapeutic target for serum LDL-C levels (< 100 mg/ dL) has been achieved. The first choice for this clinical condition is fibric acid derivates. The same therapeutic option should be considered in patients without IHD with low serum HDL-C levels and high cardiovascular risk (>20%), hypertriglyceridemia, type 2 diabetes mellitus, or metabolic syndrome. © 2004 Adis Data Information BV. All rights reserved.

引用

页码：299 / 314

页数：15

共 96 条

[1]

Goldberg I.J., Diabetic dyslipidemia: Causes and consequences, J. Clin. Endocrinol. Metab., 86, pp. 965-971, (2001)

[2]

Stein O., Stein Y., Atheroprotective mechanisms of HDL, Atherosclerosis, 144, pp. 285-301, (1999)

[3]

Badimon J.J., Badimon L., Fuster V., Regression of atherosclerosis lesions by HDL plasma fraction in the cholesterol-fed rabbit, J. Clin. Invest., 85, pp. 1234-1241, (1990)

[4]

Ginsberg H.N., Lipoprotein physiology, Endocrinol. Metab. Clin. North Am., 27, pp. 503-519, (1998)

[5]

Nissen S.E., Tsunoda T., Murat Tuzcu E., Et al., Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial, JAMA, 290, pp. 2292-2300, (2003)

[6]

Executive summary of the third report of the National Cholesterol Education Program (NCEP), JAMA, 285, pp. 2486-2497, (2001)

[7]

De Backer G., Ambrosioni E., Borch-Johnsen K., Et al., European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, Eur. Heart J., 24, pp. 1601-1610, (2003)

[8]

Austin M.A., Hokanson J.E., Edwards K.L., Hypertrigliceridemia as a cardiovascular risk factor, Am. J. Cardiol., 81, 4 SUPPL., (1998)

[9]

Grundy S.M., Low density lipoprotein, non-high density lipoprotein and apolipoprotein B as a targets of lipid-lowering therapy, Circulation, 106, pp. 2526-2529, (2002)

[10]

Sacks F.M., The role of high density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations, Am. J. Cardiol., 90, pp. 139-143, (2002)

← 1 2 3 4 5 6 7 8 9 10 →